1. Home
  2. TWIN vs NGNE Comparison

TWIN vs NGNE Comparison

Compare TWIN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$14.82

Market Cap

269.7M

Sector

Industrials

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$21.51

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
NGNE
Founded
1918
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.7M
327.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
TWIN
NGNE
Price
$14.82
$21.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$12.00
$60.13
AVG Volume (30 Days)
44.1K
156.3K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
1.06%
N/A
EPS Growth
N/A
N/A
EPS
1.53
N/A
Revenue
$340,738,000.00
$925,000.00
Revenue This Year
$10.79
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$9.84
N/A
Revenue Growth
15.45
N/A
52 Week Low
$6.16
$6.88
52 Week High
$19.63
$37.27

Technical Indicators

Market Signals
Indicator
TWIN
NGNE
Relative Strength Index (RSI) 34.88 51.75
Support Level $14.80 $19.44
Resistance Level $14.93 $21.90
Average True Range (ATR) 0.82 2.35
MACD -0.35 0.07
Stochastic Oscillator 7.24 33.98

Price Performance

Historical Comparison
TWIN
NGNE

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: